NCT01941849: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma |
|
|
| Withdrawn | 1 | 0 | Europe | Vandetanib, Caprelsa, 131I-mIBG, Iodine-131 labelled Meta-iodobenzylguanine | University College, London, Cancer Research UK, AstraZeneca | Phaeochromocytoma, Paraganglioma | 12/15 | 12/15 | | |
